skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Effectiveness, tolerability and safety of azithromycin 1% in DuraSite® for acute bacterial conjunctivitis

Review

(1951) Views  (579) Full article downloads

Authors: Susannah McLean, Aziz Sheikh

Published Date April 2010 Volume 2010:4 Pages 69 - 76
DOI: http://dx.doi.org/10.2147/PPA.S4203

Susannah McLean, Aziz Sheikh

Centre for Population Health Sciences: GP Section, Allergy and Respiratory Research Group, University of Edinburgh, Medical School, Edinburgh, United Kingdom

Purpose: Bacterial eye infections are commonly treated with topical antibiotics, despite limited evidence of effectiveness. Azithromycin 1% in DuraSite® is a new formulation of azithromycin in a gel polymer designed for use in acute bacterial conjunctivitis.

Methods: We conducted systematic searches of the Cochrane Database of Clinical Trials, PubMed and Google Scholar to find randomized controlled trials of “­azithromycin DuraSite®”. These searches of published literature were supplemented with searches for unpublished trials and trials in progress.

Results: We found six reports of randomized controlled trials investigating the role of azithromycin 1% in DuraSite® for the management of acute bacterial conjunctivitis. The quality of these trials was judged to be moderate to high. These trials assessed effectiveness, tolerability and safety outcomes, but we found no trials looking at cost-effectiveness. DuraSite® is a relatively stable formulation and so azithromycin 1% in DuraSite® has a simpler dosing schedule than other available topical antibiotics. It appears to be similar to other topical antibiotics in its effectiveness, but minor side effects are quite common.

Conclusion: Acute bacterial conjunctivitis is a relatively mild, typically self-limiting, infection. Antibiotics should seldom be required. If, however, a decision to prescribe antibiotics is made, azithromycin 1% in DuraSite® is likely to be broadly comparable in its effectiveness to most other antibiotics used to treat acute bacterial conjunctivitis. Further research is needed to determine its cost-effectiveness.

Keywords: conjunctivitis, bacterial eye infection, azithromycin 1% in DuraSite®








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
Evaluation of olopatadine 0.2% in the complete prevention of ocular itching in the conjunctival allergen challenge model
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
Comparative efficacy of topical tetracaine solution versus lidocaine gel in cataract surgery